SG100
Pre-clinical- Indications
- Allergic asthma
Company intelligence / Profile preview
S-TARget therapeutics
Vienna, Vienna State, Austriaat.linkedin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
S-TARget therapeutics has demonstrated proof-of-concept for its lead vaccine candidate SG100 in non-human primate models, showing induction of a healthy Th1 immune response against house dust mite allergens. The company’s approach aims to remodel existing allergic responses at the cellular level, potentially providing a curative therapy rather than symptomatic relief. Follow-on studies were planned to further validate efficacy and safety before entering clinical trials
- Therapeutic areas
- Immunology
- Modalities
- VaccineBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Allergopharma/Merck KGaA entered into a licensing agreement with S-TARget therapeutics for allergy vaccine development in September 2014
Beyond the preview
Go deeper on S-TARget therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-TARget therapeutics.